Lupin's shares are expected to attract investor attention as the company received U.S. FDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets.
Lupin shares to be in focus on Thursday as USFDA approves Dapagliflozin and Metformin tablets
